Development of modified release systems for use in early preclinical studies

In preclinical drug development, rapid absorption and elimination of drugs often results in heavily fluctuating plasma levels. These fluctuations are often undesired and an ideal formulation would rather release the drug in a controlled way, keeping plasma levels relatively constant over a prolonged period of time. Early drug development generally struggle with limitations in amount of drug substance available for formulation development. Hence, it is often difficult to develop robust modified release formulations in this early phase. In this diploma work we would like to examine modified release formulations applicable on a broad spectrum of drug compounds. These systems need to be in situ gelling formulations, ie drug formulations that are dosed as solutions which form gels in vivo (following oral or subcutaneous dosing). They should be possible to develop using only small amounts of drug. A small scale approach for analysis of release kinetics will be used to evaluate the developed formulations. If successful, the modified release formulation might be tested in vivo.

Key words: Pharmaceutical Science, Modified Release, In situ gelling, Biopharmacy, Physical chemistry, Analytical chemistry

Contact persons:

Thomas Meijer 08 55328785
[email protected]

Stefanie Thelig 08 55328785
[email protected]